NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Prostate Cancer. These NCCN Guidelines™ are currently available as Version 3.2010.
The NCCN Guidelines for Prostate Cancer have been updated to include cabazitaxel with steroids as an option under systemic salvage therapy of metastatic castration-recurrent prostate cancer (category 1 designation). Cabazitaxel given with prednisone has been shown in a randomized phase III study to prolong overall survival, progression-free survival, and improve PSA and radiologic responses when compared with mitoxantrone and prednisone. Cabazitaxel is FDA-approved in the post-docetaxel second line setting.
For the complete updated versions of the NCCN Guidelines™ and the NCCN Compendium™ please visit NCCN.org.